Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Ethnopharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1603316

Qingda granule prevents Ang II-induced cardiac hypertrophy via inhibiting NF-κB signaling pathway

Provisionally accepted
Yuhang  GongYuhang GongDa  WoDa WoCanran  WangCanran WangRuokun  HuangRuokun HuangEn  MaEn MaCeliang  WuCeliang WuJun  PengJun PengWeidong  ZhuWeidong ZhuDan-ni  RenDan-ni Ren*
  • Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian Province, China

The final, formatted version of the article will be published soon.

Background: Angiotensin II (Ang II) type 1 receptor (AT1R) signaling pathway is a key component of the renin-angiotensin-aldosterone system (RAAS) that is involved in the development of hypertension. Chronic Ang II overactivation results in pathological cardiac hypertrophy that progresses into decompensated cardiac dysfunction and impairment. Qingda granule (QDG) is a Traditional Chinese formula that has been used clinically in treating hypertension and its complications. Purpose: This study aimed to elucidate the role and underlying mechanisms of QDG in preventing Ang II-induced cardiac hypertrophy. Methods: We used chronic Ang II infusion via minipumps in mice and administered QDG daily to examine the effects of QDG on preventing hypertension and various parameters of cardiac impairment. Results: QDG treatment significantly reduced Ang II-induced elevation in blood pressure. Furthermore, QDG exerted a robust cardioprotective effect on chronic Ang II-induced cardiac hypertrophy and decompensated cardiac dysfunction. QDG also inhibited Ang II-induced adverse NF-κB signaling activation and downstream pro-inflammatory targets, which were prevented via administration with SC75741, a specific NF-κB inhibitor. Conclusion: Our findings provide further insight into the robust ability of QDG in preventing Ang II-induced cardiac hypertrophy via preventing NF-κB signaling activation and implicate its use in the clinical treatment of hypertension and cardiac hypertrophy.

Keywords: Qingda granule, Angiotensin II, Hypertrophy, Cardiac impairment, NF-κB signaling

Received: 04 Apr 2025; Accepted: 21 Aug 2025.

Copyright: © 2025 Gong, Wo, Wang, Huang, Ma, Wu, Peng, Zhu and Ren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dan-ni Ren, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, Fujian Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.